[go: up one dir, main page]

WO2004069229A1 - Medicaments antidiabetiques a double liberation et procede de production de ceux-ci - Google Patents

Medicaments antidiabetiques a double liberation et procede de production de ceux-ci Download PDF

Info

Publication number
WO2004069229A1
WO2004069229A1 PCT/IN2003/000313 IN0300313W WO2004069229A1 WO 2004069229 A1 WO2004069229 A1 WO 2004069229A1 IN 0300313 W IN0300313 W IN 0300313W WO 2004069229 A1 WO2004069229 A1 WO 2004069229A1
Authority
WO
WIPO (PCT)
Prior art keywords
pharmaceutical composition
active agent
composition according
pharmaceutically active
matrix material
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/IN2003/000313
Other languages
English (en)
Inventor
Ramachandran Thembalath
Yatish Kumar Bansal
Vaishali Manish B-2 14th Forjett Terrace TAWDE
Vivek Kamlakar Jadhav
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ipca Laboratories Ltd
Original Assignee
Ipca Laboratories Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ipca Laboratories Ltd filed Critical Ipca Laboratories Ltd
Priority to AU2003282377A priority Critical patent/AU2003282377A1/en
Publication of WO2004069229A1 publication Critical patent/WO2004069229A1/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Definitions

  • the invention relates to the field of medicine and pharmacology. More specifically, the invention relates to a pharmaceutical composition comprising at least two different pharmaceutically active ingredients, the release profile of a first active ingredient being different from the release profile of a second active ingredient.
  • the pharmaceutical composition of the invention is particularly indicated in the treatment of diabetes.
  • Diabetes mellitus is a group of disorders of carbohydrate metabolism in which the action of insulin is diminished or absent through altered secretion, decreased insulin activity or a combination of both factors.
  • IDDM insulin-dependent diabetes mellitus
  • NIDDM non- insulin-dependent diabetes mellitus
  • Type II diabetes mellitus is a common disease increasingly affecting people worldwide. While type II diabetes affects less than 10% of the population in developed countries, the prevalence of the disease is growing faster among the Asian population especially Asian immigrants. Antidiabetic drugs have therefore become an area of immense interest and attention for the research community throughout the world.
  • First line therapy in both type I and type II diabetes involves dietary control and, especially in the case of type II diabetes, increased exercise routine. If patients with type II diabetes have not achieved suitable control within about three months after dietary modification and increased physical activity, then oral hypoglycemic drugs may be indicated.
  • the two major classes of such drugs are thiazolinediones and biguanides.
  • Thiazolinediones act mainly by enhancing insulin sensitivity in peripheral tissues. Biguanides act chiefly by decreasing hepatic gluconeogeneis and increasing peripheral utilization of glucose.
  • Metformin (N, N - dimethyl imidocarbonimidic diamide) is a typical biguanide and is an active ingredient used in oral hypoglycemic drugs for the treatment of type II diabetes mellitus in humans and other mammals. It is typically administered in the form of a pharmaceutically acceptable salt, usually a hydrochloride salt. Metformin is not chemically or pharmacologically related to any other class of hypoglycemic agents. Unless otherwise indicated, this specification will use "metformin" to mean metformin and pharmaceutically acceptable salts thereof. Metformin is often indicated for patients who are not effectively treated with a thiazolinedione drug independently.
  • Metformin hydrochloride is a white to off-white crystalline compound having the molecular formula C H ⁇ N 5 .HCl (molecular wt. 165.63) and is freely soluble in water and practically insoluble in acetone, ether and chloroform.
  • Oral doses of metformin are generally recommended in the range of 500 to 2500 mg a day and a single dose may vary from 500 to 850 mg.
  • Metformin can exert its hypoglycemic effect even in the absence of insulin, particularly in patients who are not effectively treated with sulfonylureas.
  • Pioglitazone belongs to the class of thiazolinediones which act primarily by decreasing insulin resistance. They partially mimic certain actions of insulin on carbohydrate and lipid metabolism in type II diabetes mellitus and other conditions of insulin resistance. Pioglitazone, rosiglitazone and troglitazone are the most commonly used thiazolinediones (glitazones).
  • Metformin is not chemically related to thiazolinediones, but it is routinely used in combination with a thiazolinedione, such as troglitazone, pioglitazone, etc., and shows synergistic properties in some cases.
  • Other biguanides such as phenformin and buformin can also be used in combination with metformin.
  • US Patent 6,011,049 discloses a combination therapy for metformin along with a thiazolinedione and establishes unexpected biological benefits of these combinations in the context of conventional drug formulation.
  • US Patent 6,372,255 describes a tablet for instant and prolonged release of one or more active substances, by means of concentric superposed layers using a non-biodegradable, inert porous polymetric matrix comprising ethyl acrylate and methyl methacrylate copolymers.
  • US Patent 6,403,121 and US Patent 6,451,342 describe a controlled release formulation of pioglitazone with metformin and troglitazone with metformin respectively. These drugs are subjected to controlled release using silicates and alginates (poly saccharides) as modulating release agents.
  • US Patent 6,475,521 claims a biphasic controlled release delivery system for high solubility pharmaceuticals including metformin.
  • the emphasis is on controlled release and extended release using biphasic layers of a single active ingredient.
  • Pioglitazone hydrochloride being relatively non-polar, has relatively low solubility and therefore its absorption is dependent on its dissolution rate in the contents of the gastro- intenstinal tract, in contrast to metformin which is highly soluble.
  • Metformin is usually used in the form of metformin hydrochloride.
  • Metformin hydrochloride has a very high water solubility (>300mg/ml at 25°C). This high solubility of metformin leads to difficulty in providing a slow release rate from a formulation. Controlling the initial burst of metformin in a formulation containing more than one active ingredients is a problem often encountered. This problem is further complicated due to the high dosage of 500mg and above which is required for treatment.
  • US Patent 6,031,004 describes a method for the treatment of diabetes employing metformin hydrochloride and other salts by themselves or in combination with another anti-diabetic agent (e.g. a hypoglycemic agent such as glyburide, glipizide, pioglitazone, acarbose, miglitol, troglitazone or insulin).
  • a hypoglycemic agent such as glyburide, glipizide, pioglitazone, acarbose, miglitol, troglitazone or insulin.
  • the dosage is disclosed as an oral tablet form.
  • Metformin salts of dibasic acids that are equivalent to metformin hydrochloride are also described.
  • US Patent 6,475,521 discloses a biphasic controlled release system for high solubility pharmaceuticals.
  • a metformin hydrochloride salt or a salt of metformin with a dibasic acid is used in combination with another hypoglycemic agent, for example a thiazolinedione such as glyburide, pioglitazone, glipizide, gliclazide or chlorpropamide, for the treatment of diabetes.
  • a suitable excipient a hydrophilic and/or hydrophobic polymer
  • US Patent 6,524,618 describes an extended-release matrix formulation capable of being directly compressed into tablets comprising metformin hydrochloride blended with specific excipients in the form of a free flowing powder.
  • Metformin hydrochloride is also used in combination with another anti-diabetic agents selected from the group consisting of thiazolinediones (eg. pioglitazone, glipyride, glipizide, glyburide, and gliciazide), ⁇ - glucosidaze inhibitors and glitazones as well as combinations of two or more of the foregoing anti-diabetic agents.
  • WO-A-02094285 describes orally administered galenic preparations (such as tablets, capsules, powders and the like), which consist of biguanide, preferably metformin and at least one other hypoglycemic active agent (glibenclamide, pioglitazone hydrochloride, rosiglitazone maleate, nateglinide, glipizide, pioglitazone).
  • This capsule-shaped tablet consists of a core based on metformin further coated with a film that enables prolonged release in vivo of metformin.
  • the capsule may be coated with the said at least one other hypoglycemic active agent and may allow for the prolonged release of the agent.
  • combination preparations with active agents are known in the prior art for the treatment of diabetes, the combination agents are generally released simultaneously either at administration or over a period of time.
  • Such preparations although convenient, may not be as effective for treatment as two separately administered doses of individual active agents and this may be for a number of reasons. For example, one agent may require a slower release profile in relation to another agent in order to be effective. It may also be the case that both agents have similar modes of pharmacological action and the action of one or both may therefore be inhibited by simultaneous release with the other because both are competing for the same or similar receptor.
  • a pharmaceutical composition comprising a matrix material having first pharmaceutically active agent dispersed therein, the dispersion of the first agent within the matrix material being effective to delay the release profile on administration of the pharmaceutical composition with respect to the release profile of a second pharmaceutically active agent provided in the composition outside of the matrix material.
  • the first pharmaceutically active agent and the second pharmaceutically active agent may, in one preferred composition according to the invention, be independently indicated in the treatment of diabetes.
  • the first pharmaceutically active agent and the second pharmaceutically active agent are selected from respectively different classes of chemical compound.
  • the first and second active agents in the composition may be selected to exhibit a synergistic effect for treatment of a disease or a condition, such as diabetes.
  • the first pharmaceutically active agent is a biguanide compound, preferably metformin.
  • the second pharmaceutically active agent is a thiazolinedione compound, preferably pioglitazone.
  • the matrix material is preferably a polymeric material or mixture of polymeric materials and is preferably insoluble or only sparingly soluble in water.
  • the matrix material has the capacity to absorb water from its surrounding environment and to swell on such abso ⁇ tion.
  • Preferred polymeric materials include carbomers, such as carbomer 971, cellulosic polymers and alkyl cellulosic polymers such as methyl cellulose, ethyl cellulose, hydroxyethyl cellulose, hydroxy propyl cellulose, hydroxypropyl methyl cellulose, hydroxypropyl methyl cellulose phthalate and mixtures of two or more thereof. Hydroxypropyl methyl cellulose is especially preferred, preferably with a viscosity in the range of 15000 - 100000 cps. Combinations of carbomers with cellulosic polymers are also particularly suitable as the matrix material.
  • the matrix material is biodegradable.
  • the polymer of the matrix material may account for 15-25% or 15-20% of the total mass of the pharmaceutical composition
  • the first pharmaceutically active agent is dispersed substantially homogenously throughout the matrix material.
  • the release profile of the second pharmaceutically active agent be such that release of the second agent begins only a short time, for example in less than about 30 minutes, preferably less than about 15 minutes and most preferably less than about 5 minutes after administration. Release of the second agent may begin substantially immediately after administration. Release of the first pharmaceutically active agent is delayed relative to the second agent, and may also be extended to take place over a longer timescale with respect to the second agent.
  • the second pharmaceutically active agent is less soluble in water, preferably substantially less soluble in water, than the first pharmaceutically active agent.
  • the second pharmaceutically active agent may be insoluble, or only sparingly soluble, in water.
  • the second active agent thiazolinedione for example, may conveniently be provided in combination with a solubilising agent to provide a predetermined substantially immediate release on administration of the composition.
  • a solubilising agent to provide a predetermined substantially immediate release on administration of the composition.
  • Sodium lauryl sulphate is one preferred solubilising agent, which may suitably be present in an amount of from 0.2-2% of the total mass of the composition.
  • the second active agent may be therefore provided in combination with an effective amount of one or more immediate release excipients selected, for example, from one or more of: sodium starch glycolate, sodium lauryl sulphate, croscarmellose sodium and betacyclodextrin.
  • one or more immediate release excipients selected, for example, from one or more of: sodium starch glycolate, sodium lauryl sulphate, croscarmellose sodium and betacyclodextrin.
  • the pharmaceutical composition of the invention is suitably provided in a tablet form for oral administration and is preferably provided as a layered tablet, with a first layer comprising the matrix material and the first pharmaceutically active agent (optionally in combination with other excipients, colourants, binders, diluents, disintegrants, fillers, lubricants, glidants, taste-masking agents and the like) and a second layer comprising the second pharmaceutically active agent (optionally in combination with other exipients, colourants, diluents, disintegrants, binders, fillers, lubricants, glidants, taste-masking agents and the like).
  • the first active agent may suitably be present in the first layer in an amount ranging from 500 mg to 850 mg.
  • the second active agent may suitably be present in the second layer in an amount ranging from 15 mg to 45 mg.
  • binding agent When a binding agent is present in the composition, preferred binding agents (for combination with the first active agent) include polyvinylpyrrolidone, starch or mixtures thereof. When present, polyvinylpyrrolidone preferably has a grade varying from 10 - 120. The percentage of binding agent, when present, is preferably from 1-10% of the total mass of the composition. When polyvinylpyrrolidone is used as the binding agent it may be of K value 90 or with grade 90.
  • preferred diluents include micro crystalline cellulose, starch and lactose. Such diluents, when used, may suitably be present in an amount of from 5-10% of the total mass of the composition.
  • preferred diluents include microcrystalline cellulose, dicalcium phosphate or mixtures thereof. Such diluents may suitably be present in an amount of from 10 - 20 % of the total mass of the composition.
  • preferred disintegrants include sodium starch glycolate and croscarmellose sodium. Such disintegrants may suitably be present in an amount of from 0.2-2% of the total mass of the composition.
  • a preferred lubricant is magnesium stearate.
  • Such lubricants may suitably be present in an amount of from 0.01-0.02% of the total mass of the preparation.
  • a preferred glidant is colloidal silicon dioxide.
  • Such glidants may suitably be present in an amount of from 1-2% of the total mass of the composition.
  • the invention provides a pharmaceutical preparation in tablet form comprising two or more active ingredients with pre-determined release profiles, at least one active ingredient having a release profile that differs substantially from the release profile of another of the other active ingredient.
  • Preferred pharmaceutical compositions of the invention will: provide immediate release of thiazolinedione by using a solubilizing agent in an effective manner in a first layer; use a combination of two specific hydroxypropyl methyl cellulose and/or carbomer polymers in a second layer to aid effective release of the drug over a specific period of time independent of pH affects; provide a two drug combination therapy having a synergistic effect over control of blood glucose in diabetic patients; allow reduced frequency of drug dosing and hence improve patient compliance; maintain a steady drug concentration in the blood circulation with the help of a sustained release layer; and minimize incidence and severity of adverse side effects.
  • the present invention therefore relates to a pharmaceutical composition adapted for dual release at different rates of combined pharmaceutical active agents, for example agents having anti-diabetic activity, in which at least one of the active ingredients is, preferably homogenously, dispersed throughout a rate controlling polymer matrix, release of the at least one active ingredient being controlled by diffusion through the matrix, and in which at least one other active agent is provided in the composition in a form available for rapid release in vivo.
  • combined pharmaceutical active agents for example agents having anti-diabetic activity
  • at least one of the active ingredients is, preferably homogenously, dispersed throughout a rate controlling polymer matrix, release of the at least one active ingredient being controlled by diffusion through the matrix, and in which at least one other active agent is provided in the composition in a form available for rapid release in vivo.
  • a pharmaceutical preparation in tablet form comprising two or more active ingredients with pre-determined release profiles, at least one active ingredient having a release profile that differs substantially from the release profile of at least one other active ingredient.
  • Each active ingredient may be disposed in a discrete layer within the tablet.
  • the at least two release profiles may comprise an extended release profile and an immediate release profile.
  • the present invention also relates to the pharmaceutical preparation of a bi-layer tablet suitable for oral administration.
  • Each tablet is preferably made up of immediate release compartment and extended release compartment.
  • the immediate release compartment may comprise a compressed blend of an active agent and one or more polymers with some super disintegrant and solubilisers.
  • the extended release compartment may comprise biodegradable/non-biodegradable or hydrophilic /hydrophobic polymers which have swelling properties within which an active ingredient is suitably blended and this allows prolonged release of active substance within the second layer.
  • the extended release compartment When the extended release compartment is in contact with the immediate release compartment it provides a dose sufficient to exceed the metabolic capacity of the body and maintains the therapeutic. levels.
  • the invention is not limited as to the nature of the active ingredients.
  • Each layer may contain a different active ingredient.
  • the first layer may contain up to 50-80% of the active substance of the total weight of the first layer.
  • the second layer may contain up to 3-10% by weight of the active ingredient.
  • Drug efficacy generally depends on the ability of the drug to reach its target in sufficient quantities, to maintain desired therapeutic levels for a fixed (desired) time period.
  • Metformin and pioglitazone are two active ingredients for anti-diabetic drugs that are used to treat diabetic patients (human beings).
  • the matrix material polymer is associated to the biguanide by forming a core within the preparation to provide a predetermined delay in the time period of the release of the biguanide.
  • compartmentalized (two compartments or more) delivery of active ingredients in the intestinal tract is facilitated by the product formulation, taking into account the physical & physiological conditions in the human GI tract and also the travelling time of the pharmaceutical preparation through the intestinal tract.
  • the immediate release ingredient releases within 45 minutes in acidic pH (stomach), and the extended release ingredient releases within 10 hrs at a different pH.
  • Orally administered drugs have to overcome several obstacles to reach their desired targets. Before orally administered drugs enter the general circulation of the human body they are absorbed into the capillaries and veins of the GI tract and are transported by the portal vein to the liver. The pH and enzymatic activities found in the GI tract fluids may inactivate the drug or cause the drug to dissolve poorly. Thus the amount of drugs in the blood stream is significantly lower than the amount administered. This metabolic elimination of the given dose results in bioavailability.
  • Formulations capable of immediate and sustained release are suitable for once daily administration. Therefore, in accordance with the present invention, there is provided a multilayer formulation that provides dual release of two different pharmaceutically active agents in an effective manner in single dosage form. Furthermore, the present invention may provide immediate release of thiazolinedione by using a solubilizing agent in an effective manner in an upper layer.
  • the use of a combination of two specific hydroxypropyl methyl cellulose polymers in the lower layer helps for the drug to release effectively over a specific period of time independent of pH affects.
  • the two drugs in the combination therapy are selected to have a synergetic effect over control of glucose in blood in diabetic patients.
  • the combination therapy formulation may assist in the reduced frequency of drug dosing and hence improving patient compliance.
  • the formulation preferably maintains a steady drug concentration in blood circulation with the help of sustained release layer and minimises incidence and severity of adverse side effects.
  • the multi-layer formulation is such that the upper layer comprises pioglitazone hydrochloride which is formulated by using solubilizing agent, disintegrating agent and wetting agent to make it effective for immediate release and the second layer which may or may not separate upper layer and lower layer which may or may not comprise metformin with a portion or all the amount of cellulose polymer depending upon the rate of release of the core preparation.
  • the present invention relates to a process for dual release combination of pharmaceutical active ingredients, more particularly, antidiabetic drugs, comprising extended release of biguanide and immediate release of thiazolinedione in a multi-layer formulation.
  • Non-aqueous vehicle q.s.
  • the tablets of the invention are prepared by a method including the steps of granulation, followed by compression. Accordingly, the present invention further provides a method for forming a tablet-form pharmaceutical composition comprising: providing a first pulverulent component comprising a first pharmaceutically active agent and a matrix material; providing a second pulverulent component comprising a second pharmaceutically active agent; and compressing the first and second pulverulent components together as discrete layers to form a tablet-form pharmaceutical composition having a first layer comprising the matrix material having the first pharmaceutically active agent dispersed therein, the dispersion of the first agent within the matrix material being effective to delay the release profile on administration of the pharmaceutical composition with respect to the release profile of the second pharmaceutically active agent provided in the composition as a second discrete layer.
  • the method of preparation comprises the steps of: a) preparing granules of a first active substance from a pulverulent mixture of the said first active substance and one or more biodegradable inert polymeric materials, and optionally one or more additives suitable for the prolonged release of the said first active substance; b) preparing granules of second active substance from a pulverulent mixture of the said second active substance, a disintegrating agent, a solubilising agent, optionally one or more additives such as binding agent and polymers for the preparation of the immediate release of the second active substance; and c) combining, by compressing, in a manner known per se the two types of granules obtained in steps a) and b) above so as to obtain tablets in which the lower layer, affording prolonged release, results from the compression of granules obtained in step a) and in which the upper layer, affording immediate release, results from the compression of the granules in step b).
  • the first step (a) is designed to provide granules based on the first active substance, which will lead , through compression, to the lower layer, designated as the prolonged release layer.
  • the constituents of this layer are those of the biodegradable inert polymeric matrix defined above.
  • the second step (b) is designed to provide granules based on a different active substance, which will lead, through compression, to the upper layer, designated the immediate release layer.
  • Step c) leads to successive compression of the granules obtained in the preceding steps a) and b) to form a tablet.
  • Steps (a) and (b) involve the granulation of powder of amorphous or crystallized particles. This granulation is carried out by a wet granulation method.
  • the method of granulation comprises five steps;
  • Dry mixing consists of mixing the pulverulent excipients entering into the composition of the granules.
  • the wetting consists in adding to the pulverulent mixture, various constituents, an aqueous solution of binder or hydroalcoholic solution of binder or alcoholic solution of binder.
  • the granulation procedure is carried out by kneading, in a planetary or rapid type mixer granulator.
  • the drying procedure is carried out in a fluid bed dryer or tray dryer to achieve desired loss on drying. Sizing is done in a multimill by using suitably sized sieves to obtain the desired-size distribution of the granules.
  • Excipients which may be used include:
  • Water has no environmental problems of health hazards to the workers and eliminates the necessity of solvent recovery system.
  • Non-releasing controlling excipient, glidant promotes granulate flow by reduction of interparticulate friction.
  • Disintegrant it is used as a disintegrant in tablet formulation. Disintegration occurs by rapid uptake of water followed by rapid and enormous swelling. Usual concentration used in a formulation is between 2% to 8%.
  • Croscarmellose Sodium
  • croscarmellose sodium When used in wet granulation the croscarmellose sodium is best added in both the wet and dry stages of the process so that the wicking and swelling ability of the disintegrant is best utilised.
  • Figure 1 shows a bilayer tablet produced in accordance with the present invention.
  • Part (A) is an upper view of the tablet that has a flat beveled edge 1.
  • Part (B) is a plan view of a tablet wherein the width 2 of the tablet which is 9mm and the length 3 of the tablet is 19mm.
  • Part (C) is a side view of the tablet wherein the shape of the tablet is capsule shaped and the two layers are distinguished as the upper layer 4 and the lower layer 5.
  • “PM 30" is the embossing or engraving on the tablet as an identification and distinguishing feature and also to prevent counterfeiting.
  • Multilayer tablets of the invention are particularly advantageous since their method of preparation is simple, the excipient constituting them being customary. Furthermore it is possible by appropriately selecting the biodegradable inert polymeric materials to achieve accuracy in the dissolution profile to a very large extent and with precision, depending on the needs.
  • the polymeric materials belong to the hydroxypropyl methyl cellulose group, because of the diversity properties of the polymers, it is possible to obtain modulation of the release of active ingredients.
  • magnesium stearate was mixed with the powder.
  • magnesium stearate colloidal silicon dioxide and sodium starch glycolate
  • the components except magnesium stearate, colloidal silicon dioxide and sodium starch glycolate, were mixed together and granulated using a paste containing polyvinylpyrrolidone.
  • the granules were dried and screened to obtain a suitable size distribution, and mixed with colloidal silicon dioxide and croscarmellose sodium in a blender. When this mixture had been effectively blended, magnesium stearate were mixed with the powder.
  • Bilayer tablets each of 19 x 9mm dimension and each containing 500 mg of metformin hydrochloride and 15 mg of pioglitazone, were then produced in a tablet press by a two stage pressing procedure. First the lower layer (weighing 930mg) was pressed and then the ingredients for the upper layer (weighing 250g) were added to the press. Re-pressing produced a two-layer tablet weighing 1180mg.
  • Metformin Hydrochloride 56.8%% w/w Hydroxypropylmethyl Cellulose (100,000 cps) 15% w/w
  • magnesium stearate was mixed with the powder.
  • Pioglitazone Hydrochloride 6.8% w/w Microcrystalline Cellulose 50% w/w Lactose 33% w/w Polyvinylpyrrolidone 4% w/w Sodium Lauryl Sulphate 0.8% w/w Lake of Sunset Yellow 0.4% w/w Croscarmellose Sodium 3% w/w Colloidal Silicon Dioxide 1% w/w Sodium Starch Glycolate 0.4% w/w Magnesium Stearate 0.4% w/w/w
  • magnesium stearate and colloidal silicon dioxide were mixed together and granulated using a paste containing polyvinylpyrrolidone.
  • the granules were dried and screened to obtain a suitable size distribution, and mixed with colloidal silicon dioxide and croscarmellose sodium in a blender. When this mixture had been effectively blended, magnesium stearate were mixed with the powder.
  • Bilayer tablets each of 19 x 9mm dimension and each containing 500 mg of metformin hydrochloride and 15 mg of pioglitazone, were then produced in a tablet press by a two stage pressing procedure. First the lower layer (weighing 880mg) was pressed and then the ingredients for the upper layer (weighing 250g) were added to the press. Re-pressing produced a two-layer tablet weighing 1130mg.
  • magnesium stearate was mixed with the powder.
  • magnesium stearate and colloidal silicon dioxide were mixed together and granulated using a paste containing polyvinylpyrrolidone.
  • the granules were dried and screened to obtain a suitable size distribution, and mixed with colloidal silicon dioxide and croscarmellose sodium in a blender. When this mixture had been effectively blended, magnesium stearate were mixed with the powder.
  • Bilayer tablets each of 19 x 9mm dimension and each containing 500 mg of metformin hydrochloride and 30 mg of pioglitazone, were then produced in a tablet press by a two stage pressing procedure. First the lower layer (weighing 900mg) was pressed and then the ingredients for the upper layer (weighing 230g) were added to the press. Re-pressing produced a two-layer tablet weighing 1130mg.
  • magnesium stearate was mixed with the powder.
  • Pioglitazone Hydrochloride 8.23% w/w Microcrystalline Cellulose 49.0% w/w Lactose 30% w/w
  • magnesium stearate and colloidal silicon dioxide were mixed together and granulated using a paste containing polyvinylpyrrolidone.
  • the granules were dried and screened to obtain a suitable size distribution, and mixed with colloidal silicon dioxide and croscarmellose sodium in a blender. When this mixture had been effectively blended, magnesium stearate were mixed with the powder.
  • Bilayer tablets each of 19 x 9mm dimension and each containing 500 mg of metformin hydrochloride and 15 mg of pioglitazone, were then produced in a tablet press by a two stage pressing procedure. First the lower layer (weighing 890mg) was pressed and then the ingredients for the upper layer (weighing 240g) were added to the press. Re-pressing produced a two-layer tablet weighing 1130mg.
  • Metformin Hydrochloride 55.5% w/w
  • magnesium stearate was mixed with the powder.
  • Pioglitazone Hydrochloride 14.6% w/w Microcrystalline Cellulose 33% w/w Lactose 33.0% w/w
  • magnesium stearate and colloidal silicon dioxide were mixed together and granulated using a paste containing starch.
  • the granules were dried and screened to obtain a suitable size distribution, and mixed with colloidal silicon dioxide and croscarmellose sodium in a blender. When this mixture had been effectively blended, magnesium stearate were mixed with the powder.
  • Bilayer tablets each of 19 x 9mm dimension and each containing 500 mg of metformin hydrochloride and 30mg of pioglitazone, were then produced in a tablet press by a two stage pressing procedure. First the lower layer (weighing 900mg) was pressed and then the ingredients for the upper layer (weighing 230g) were added to the press. Re-pressing produced a two-layer tablet weighing 1130mg.

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)

Abstract

L'invention concerne un procédé permettant une double libération combinée d'ingrédients pharmaceutiques, plus particulièrement de médicaments antidiabétiques, qui comprend la libération prolongée de biguanide et la libération immédiate de thiazolinedione dans une formulation multicouche.
PCT/IN2003/000313 2003-02-05 2003-09-17 Medicaments antidiabetiques a double liberation et procede de production de ceux-ci Ceased WO2004069229A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2003282377A AU2003282377A1 (en) 2003-02-05 2003-09-17 Dual release anti-diabetic drugs and process of production thereof

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN152MU2003 2003-02-05
IN152/MUM/2003 2003-02-05

Publications (1)

Publication Number Publication Date
WO2004069229A1 true WO2004069229A1 (fr) 2004-08-19

Family

ID=32843823

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IN2003/000313 Ceased WO2004069229A1 (fr) 2003-02-05 2003-09-17 Medicaments antidiabetiques a double liberation et procede de production de ceux-ci

Country Status (2)

Country Link
AU (1) AU2003282377A1 (fr)
WO (1) WO2004069229A1 (fr)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006080630A1 (fr) * 2004-09-23 2006-08-03 Handok Pharmaceuticals Co., Ltd. Preparation de combinaison pharmaceutique par voie orale destinee au traitement du diabete sucre
WO2007072992A3 (fr) * 2005-12-22 2007-12-06 Takeda Pharmaceutical Preparation solide
US7976853B2 (en) 2003-01-29 2011-07-12 Takeda Pharmaceutical Company Limited Process for producing coated preparation
WO2014184742A1 (fr) 2013-05-13 2014-11-20 Ranbaxy Laboratories Limited Pharmaceutical compositions containing a biguanide and a low dose antidiabetic agent

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001082875A2 (fr) * 2000-05-01 2001-11-08 Aeropharm Technology, Inc. Formulation de noyau
WO2003005991A1 (fr) * 2001-07-10 2003-01-23 Aeropharm Technology Incorporated Formulation de noyau

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001082875A2 (fr) * 2000-05-01 2001-11-08 Aeropharm Technology, Inc. Formulation de noyau
WO2003005991A1 (fr) * 2001-07-10 2003-01-23 Aeropharm Technology Incorporated Formulation de noyau

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7976853B2 (en) 2003-01-29 2011-07-12 Takeda Pharmaceutical Company Limited Process for producing coated preparation
WO2006080630A1 (fr) * 2004-09-23 2006-08-03 Handok Pharmaceuticals Co., Ltd. Preparation de combinaison pharmaceutique par voie orale destinee au traitement du diabete sucre
WO2007072992A3 (fr) * 2005-12-22 2007-12-06 Takeda Pharmaceutical Preparation solide
RU2426530C2 (ru) * 2005-12-22 2011-08-20 Такеда Фармасьютикал Компани Лимитед Твердый препарат
US8071130B2 (en) 2005-12-22 2011-12-06 Takeda Pharmaceutical Company Limited Solid preparation
AU2006328328B2 (en) * 2005-12-22 2012-08-30 Takeda Pharmaceutical Company Limited Solid preparation containing an insulin sensitizer
WO2014184742A1 (fr) 2013-05-13 2014-11-20 Ranbaxy Laboratories Limited Pharmaceutical compositions containing a biguanide and a low dose antidiabetic agent

Also Published As

Publication number Publication date
AU2003282377A1 (en) 2004-08-30

Similar Documents

Publication Publication Date Title
RU2226396C2 (ru) Твердая дозированная лекарственная форма для орального применения, содержащая комбинацию метформина и глибенкламида
US8911781B2 (en) Process of manufacture of novel drug delivery system: multilayer tablet composition of thiazolidinedione and biguanides
EP1107763B1 (fr) Comprime a liberation controlee comprenant une substance hypoglycemique et une substance antihyperglycemique
AU2005320362B2 (en) Controlled release complex formulation for oral administration of medicine for diabetes and method for the preparation thereof
US20040219209A1 (en) Controlled release metformin compositions
PL199779B1 (pl) Tabletka o dużej zawartości monosulfonianu 4-(4-metylopiperazyn-1-ylometylo)-N-[4-metylo-3-(4-pirydyn-3-ylo)pirymidyn-2-yloamino)fenylo]-benzamidu i sposób jej wytwarzania
KR20040079898A (ko) 메트포르민 및 글리벤클라미드를 포함하는 제 2형 당뇨병치료용 약제학적 조성물
JP2004523510A (ja) スペーストドラッグデリバリーシステム
US20060088594A1 (en) Highly compressible controlled delivery compositions of metformin
US20030224046A1 (en) Unit-dose combination composition for the simultaneous delivery of a short-acting and a long-acting oral hypoglycemic agent
KR101409330B1 (ko) 복용순응도가 향상된 서방성 당뇨병 치료용 복합제제 및 이의 제조방법
JP4714147B2 (ja) ロシグリタゾンおよび他の抗糖尿病剤を含有する新規組成物
US20040147564A1 (en) Combinations of glimepiride and the thiazolidinedione for treatment of diabetes
AU2014295098B2 (en) Anti-tuberculosis stable pharmaceutical composition in a form of a coated tablet comprising granules of isoniazid and granules of rifapentine and its process of preparation
US20030219482A1 (en) Multiparticulate compositions for once-a-day administration
WO2004069229A1 (fr) Medicaments antidiabetiques a double liberation et procede de production de ceux-ci
WO2003099214A2 (fr) Formulations de biguanide
WO2004091587A1 (fr) Liberation multiple de medicaments anti-diabete et procede de production associe
WO2005107717A2 (fr) Forme pharmaceutique orale pour la liberation prolongee d'un biguanide et d'une sulfonyluree
KR20060006469A (ko) 메트포르민 및 글리메피리드 복합제제를 포함하는 경구용당뇨병치료제 조성물 및 그의 제조방법
HK1039054B (en) Controlled release tablet comprising a hypoglycemic drug and an antihyperglycemic drug

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SC SD SE SG SK SL TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP